Oncology

New Study: Zai Lab’s ZEJULA Maintenance Therapy Shows Promising Results in Advanced Ovarian Cancer Patients

JAMA Oncology has just published data from the Zai Lab‘s Phase 3 PRIME study, highlighting the positive outcomes of ZEJULA (niraparib) as a first-line maintenance therapy for Chinese patients with advanced ovarian cancer. The study reveals that ZEJULA significantly prolongs progression-free survival and reduces the risk of disease progression or death by 55%. These findings offer hope for improved outcomes in a…

iSono Health Receives FDA Clearance for ATUSA, Its Automated and Wearable 3D Breast Ultrasound

iSono Health has announced U.S. Food and Drug Administration (FDA) clearance of the company’s ATUSA System for breast imaging, a first-of-its-kind compact automated whole breast ultrasound system featuring a unique wearable accessory and an intuitive software for automated image acquisition and analysis. Designed to offer enhanced efficiency, consistent accuracy and a comfortable patient experience, ATUSA’s patented technology makes 3D breast ultrasound imaging…

Y Combinator Healthcare Partner Surbhi Sarna Joins Cancer Diagnostics Company AoA Dx as an Independent Board Member

AOA Dx has announced the appointment of Surbhi Sarna as an Independent Board Member. Sarna has recently been appointed as Y Combinator’s first partner for healthcare and biotech. She is also the Founder and former CEO of nVision Medical, a medical device company that to date, is the only device cleared by the FDA to collect cells from the fallopian tube, the known…

Medtech Company Cooler Heads Adds $1.5M in New Funding After Receiving FDA Clearance to Help Save Cancer Patients’ Hair

Medtech company Cooler Heads has announced FDA clearance for its scalp cooling device to help cancer patients undergoing chemotherapy save their hair and adds $1.5M in funding to invest in commercialization. The company participated in Ad Astra’s San Diego-based accelerator program and has raised $3.1M in funding to date from Robin Hood Ventures, Anathem Ventures, Crescent Ridge Partners, Gaingels, Astia Angels, and Teal Ventures,…

Whiterabbit Partners with Solis Mammography to Increase Patient Compliance with Annual Check-ups

Whiterabbit, an AI technology company focused on early breast cancer detection, has announced a new partnership with Solis Mammography, one of the largest independent providers of breast health and diagnostic services in the United States. After pilots in multiple markets demonstrated improvement in screening mammography bookings and patient compliance, the company implemented the ACT product at more than 70 centers. Through this…

Therapixel Receives FDA Clearance for Use of Its AI-based Breast Cancer Screening Software MammoScreen on Digital Breast Tomosynthesis

Therapixel has received a second 510(k) clearance from the U.S. Food and Drug Administration (FDA) for MammoScreen, AI-based software assisting radiologists in breast cancer screening. This new clearance expands the use of Mammoscreen to Digital Breast Tomosynthesis (3D Mammography). Therapixel is a French company specialized in the design and commercialization of AI-powered medical imaging software, with the goal of delivering pertinent information…

Novarad and Ikonopedia Partner to Elevate Women’s Health in One Complete Mammography Platform

Medical software provider Novarad has formed a strategic partnership with Ikonopedia, a structured breast reporting and MQSA management system designed to improve reporting efficiency and optimize facility operations. Ikonopedia’s next-generation breast reporting and tracking system for mammography will integrate with Novarad’s NovaMG PRO mammography platform. By combining leading-edge technologies with innovative software applications to connect patient care, Novarad’s complete care platform can…

Bia Care Partners with GenesisCare to Support Women Experiencing Menopause as a Side Effect of Cancer Treatment

Around 30% of women treated for breast cancer will experience the sudden onset of menopause symptoms, as a result of their treatment. Over 200,000 women every year in England will experience this side effect during their cancer care, with no treatment currently offered as standard. If women do not receive support, a quarter will leave employment as a result of their menopause…